Focal nodular hyperplasia (FNH) and hepatic adenoma (HA) represent the most frequent non-vascular benign liver tumors. They are often asymptomatic. The widespread use of high-resolution imaging modalities leads to an increase of incidental detection of FNH and HA. Physicians are thus increasingly confronted with these formerly rarely recognized conditions, stressing the need for concise but adequate information on the optimal clinical strategies for these patients. FNH is the most common non-vascular benign tumor of the liver. It probably arises as a polyclonal, hyperplastic response to a locally disturbed blood flow. It is typically found in asymptomatic women. Histologically, FNH can be described as a focal form of cirrhosis. Complications of FNH are extremely rare and surgical resection is generally not advised. HA is a rare monoclonal, but benign liver tumor primarily found in young females using estrogen-containing contraceptives. Although its exact etiology is unknown, a direct link between sex steroid exposure and the uncontrolled hepatocellular growth is suspected. Complications of HA are spontaneous bleeding and malignant transformation. Withdrawal of estrogen treatment and excision of large tumors (>5 cm) are established therapeutic strategies. In conclusion, although FNH and HA are reasonably well-described clinical and histopathological entities, their epidemiology and pathophysiology need to be further unraveled.

Keywords:
Focal nodular hyperplasia, Hepatic adenoma, Hepatic tumor, Benign liver lesion
1.
Wanless IR, Albrecht S, Bilbao J, Frei JV, Heathcote EJ, Roberts EA, Chiasson D: Multiple focal nodular hyperplasia of the liver associated with vascular malformations of various organs and neoplasia of the brain: a new syndrome. Mod Pathol 1989;2:456–462.
2.
Rebouissou S, Bioulac-Sage P, Zucman-Rossi J: Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. J Hepatol 2008;48:163–170.
3.
Vilgrain V, Uzan F, Brancatelli G, Federle MP, Zappa M, Menu Y: Prevalence of hepatic hemangioma in patients with focal nodular hyperplasia: MRI analysis. Radiology 2003;229:75–79.
4.
Buscarini E, Danesino C, Plauchu H, de Fazio C, Olivieri C, Brambilla G, Menozzi F, et al: High prevalence of hepatic focal nodular hyperplasia in subjects with hereditary hemorrhagic telangiectasia. Ultrasound Med Biol 2004;30:1089–1097.
5.
Libbrecht L, Cassiman D, Verslype C, Maleux G, Van Hees D, Pirenne J, Nevens F, et al: Clinicopathological features of focal nodular hyperplasia-like nodules in 130 cirrhotic explant livers. Am J Gastroenterol 2006;101:2341–2346.
6.
Turowski C, Feist H, Alzen G, Gluer S, Petersen C: Conversion of a neonatal hepatic hemangioma to focal nodular hyperplasia. Pathol Int 2009;59:251–254.
7.
Sudour H, Mainard L, Baumann C, Clement L, Salmon A, Bordigoni P: Focal nodular hyperplasia of the liver following hematopoietic SCT. Bone Marrow Transplant 2009;43:127–132.
8.
Bouyn CI, Leclere J, Raimondo G, Le Pointe HD, Couanet D, Valteau-Couanet D, Hartmann O: Hepatic focal nodular hyperplasia in children previously treated for a solid tumor. Incidence, risk factors, and outcome. Cancer 2003;97:3107–3113.
9.
Nguyen BN, Flejou JF, Terris B, Belghiti J, Degott C: Focal nodular hyperplasia of the liver: a comprehensive pathologic study of 305 lesions and recognition of new histologic forms. Am J Surg Pathol 1999;23:1441–1454.
10.
Weimann A, Ringe B, Klempnauer J, Lamesch P, Gratz KF, Prokop M, Maschek H, et al: Benign liver tumors: differential diagnosis and indications for surgery. World J Surg 1997;21:983–990.
11.
Cherqui D, Rahmouni A, Charlotte F, Boulahdour H, Metreau JM, Meignan M, Fagniez PL, et al: Management of focal nodular hyperplasia and hepatocellular adenoma in young women: a series of 41 patients with clinical, radiological, and pathological correlations. Hepatology 1995;22:1674–1681.
12.
Hussain SM, Terkivatan T, Zondervan PE, Lanjouw E, de Rave S, Ijzermans JN, de Man RA: Focal nodular hyperplasia: findings at state-of-the-art MRI, US, CT, and pathologic analysis. Radiographics 2004;24:3–19.
13.
Van den Esschert JW, van Gulik TM, Phoa SSKS: Imaging modalities for focal nodular hyperplasia and hepatocellular adenoma. Dig Surg 2010;27:46–55.
14.
Strobel D, Seitz K, Blank W, Schuler A, Dietrich CF, von Herbay A, Friedrich-Rust M, et al: Tumor-specific vascularization pattern of liver metastasis, hepatocellular carcinoma, hemangioma and focal nodular hyperplasia in the differential diagnosis of 1,349 liver lesions in contrast-enhanced ultrasound. Ultraschall Med 2009;30:376–382.
15.
Trillaud H, Bruel JM, Valette PJ, Vilgrain V, Schmutz G, Oyen R, Jakubowski W, et al: Characterization of focal liver lesions with SonoVue-enhanced sonography: international multicenter study in comparison to CT and MRI. World J Gastroenterol 2009;15:3748–3756.
16.
Assy N, Nasser G, Djibre A, Beniashvili Z, Elias S, Zidan J: Characteristics of common solid liver lesions and recommendations for diagnostic workup. World J Gastroenterol 2009;15:3217–3227.
17.
Descottes B, Glineur D, Lachachi F, Valleix D, Paineau J, Hamy A, Morino M, et al: Laparoscopic liver resection of benign liver tumors. Surg Endosc 2003;17:23–30.
18.
Koffron AJ, Auffenberg G, Kung R, Abecassis M: Evaluation of 300 minimally invasive liver resections at a single institution: less is more. Ann Surg 2007;246:385–392.
19.
Karhunen PJ: Benign hepatic tumours and tumour-like conditions in men. J Clin Pathol 1986;39:183–188.
20.
Cherqui D, Mathieu D, Zafrani ES, Dhumeaux D: Focal nodular hyperplasia and hepatocellular adenoma in women. Current data (in French). Gastroenterol Clin Biol 1997;21:929–935.
21.
Wanless IR: Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2,500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 1990;11:787–797.
22.
Litten JB, Tomlinson GE: Liver tumors in children. Oncologist 2008;13:812–820.
23.
Meyers RL: Tumors of the liver in children. Surg Oncol 2007;16:195–203.
24.
Colombo M, Lencioni R, Rodes J, et al: (eds): Textbook of Hepatology. Oxford, Oxford University Press, 2008, p 1428.
25.
Ungermann L, Elias P, Zizka J, Ryska P, Klzo L: Focal nodular hyperplasia: spoke-wheel arterial pattern and other signs on dynamic contrast-enhanced ultrasonography. Eur J Radiol 2007;63:290–294.
26.
Paradis V, Benzekri A, Dargere D, Bieche I, Laurendeau I, Vilgrain V, Belghiti J, et al: Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma. Gastroenterology 2004;126:1323–1329.
27.
Bioulac-Sage P, Balabaud C, Bedossa P, Scoazec JY, Chiche L, Dhillon AP, Ferrell L, et al: Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update. J Hepatol 2007;46:521–527.
28.
Paradis V, Laurent A, Flejou JF, Vidaud M, Bedossa P: Evidence for the polyclonal nature of focal nodular hyperplasia of the liver by the study of X-chromosome inactivation. Hepatology 1997;26:891–895.
29.
Paradis V, Champault A, Ronot M, Deschamps L, Valla DC, Vidaud D, Vilgrain V, et al: Telangiectatic adenoma: an entity associated with increased body mass index and inflammation. Hepatology 2007;46:140–146.
30.
Chen YW, Jeng YM, Yeh SH, Chen PJ: P53 gene and Wnt signaling in benign neoplasms: β-catenin mutations in hepatic adenoma but not in focal nodular hyperplasia. Hepatology 2002;36:927–935.
31.
Rebouissou S, Couchy G, Libbrecht L, Balabaud C, Imbeaud S, Auffray C, Roskams T, et al: The β-catenin pathway is activated in focal nodular hyperplasia but not in cirrhotic FNH-like nodules. J Hepatol 2008;49:61–71.
32.
Paradis V, Bieche I, Dargere D, Laurendeau I, Nectoux J, Degott C, Belghiti J, et al: A quantitative gene expression study suggests a role for angiopoietins in focal nodular hyperplasia. Gastroenterology 2003;124:651–659.
33.
Haninec AL, Voskas D, Needles A, Brown AS, Foster FS, Dumont DJ: Transgenic expression of angiopoietin-1 in the liver leads to changes in lymphatic and blood vessel architecture. Biochem Biophys Res Commun 2006;345:1299–1307.
34.
Rooks JB, Ory HW, Ishak KG, Strauss LT, Greenspan JR, Hill AP, Tyler CW Jr: Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA 1979;242:644–648.
35.
Giannitrapani L, Soresi M, La Spada E, Cervello M, D’Alessandro N, Montalto G: Sex hormones and risk of liver tumor. Ann NY Acad Sci 2006;1089:228–236.
36.
Socas L, Zumbado M, Perez-Luzardo O, Ramos A, Perez C, Hernandez JR, Boada LD: Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. Br J Sports Med 2005;39:e27.
37.
Nakao A, Sakagami K, Nakata Y, Komazawa K, Amimoto T, Nakashima K, Isozaki H, et al: Multiple hepatic adenomas caused by long-term administration of androgenic steroids for aplastic anemia in association with familial adenomatous polyposis. J Gastroenterol 2000;35:557–562.
38.
Triantafyllopoulou M, Whitington PF, Melin-Aldana H, Benya EC, Brickman W: Hepatic adenoma in an adolescent with elevated androgen levels. J Pediatr Gastroenterol Nutr 2007;44:640–642.
39.
Grange JD, Guechot J, Legendre C, Giboudeau J, Darnis F, Poupon R: Liver adenoma and focal nodular hyperplasia in a man with high endogenous sex steroids. Gastroenterology 1987;93:1409–1413.
40.
Beuers U, Richter WO, Ritter MM, Wiebecke B, Schwandt P: Klinefelter’s syndrome and liver adenoma. J Clin Gastroenterol 1991;13:214–216.
41.
Labrune P, Trioche P, Duvaltier I, Chevalier P, Odievre M: Hepatocellular adenomas in glycogen storage disease type I and III: a series of 43 patients and review of the literature. J Pediatr Gastroenterol Nutr 1997;24:276–279.
42.
Greaves WO, Bhattacharya B: Hepatic adenomatosis. Arch Pathol Lab Med 2008;132:1951–1955.
43.
Terkivatan T, de Wilt JH, de Man RA, van Rijn RR, Zondervan PE, Tilanus HW, JN IJ: Indications and long-term outcome of treatment for benign hepatic tumors: a critical appraisal. Arch Surg 2001;136:1033–1038.
44.
Cho SW, Marsh JW, Steel J, Holloway SE, Heckman JT, Ochoa ER, Geller DA, et al: Surgical management of hepatocellular adenoma: take it or leave it? Ann Surg Oncol 2008;15:2795–2803.
45.
Bioulac-Sage P, Blanc JF, Rebouissou S, Balabaud C, Zucman-Rossi J: Genotype phenotype classification of hepatocellular adenoma. World J Gastroenterol 2007;13:2649– 2654.
46.
Bioulac-Sage P, Balabaud C, Zucman-Rossi J: Subtype classification of hepatocellular adenoma. Dig Surg 2010;27:39–45.
47.
Zucman-Rossi J, Jeannot E, Nhieu JT, Scoazec JY, Guettier C, Rebouissou S, Bacq Y, et al: Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 2006;43:515–524.
48.
Bluteau O, Jeannot E, Bioulac-Sage P, Marques JM, Blanc JF, Bui H, Beaudoin JC, et al: Biallelic inactivation of TCF1 in hepatic adenomas. Nat Genet 2002;32:312–315.
© 2010 S. Karger AG, Basel
2010
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.